PreveCeutical Medical Inc. (PREV.CN)
CAD 0.02
(0.0%)
CAD 0.02
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.27 Million CAD | 13.97% |
| 2022 | -1.48 Million CAD | 14.2% |
| 2021 | -1.72 Million CAD | 54.58% |
| 2020 | -3.8 Million CAD | -6.21% |
| 2019 | -3.57 Million CAD | 69.89% |
| 2018 | -11.88 Million CAD | -64.33% |
| 2017 | -7.23 Million CAD | -131.26% |
| 2016 | -3.12 Million CAD | -4907.47% |
| 2015 | -62.45 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -235.4 Thousand CAD | 44.36% |
| 2024 Q2 | -361.96 Thousand CAD | -53.76% |
| 2023 Q4 | -423.06 Thousand CAD | -76.55% |
| 2023 Q3 | -239.63 Thousand CAD | -3.93% |
| 2023 Q1 | -381.18 Thousand CAD | -214.17% |
| 2023 FY | -1.27 Million CAD | 13.97% |
| 2023 Q2 | -230.57 Thousand CAD | 39.51% |
| 2022 Q1 | -902.94 Thousand CAD | -92.45% |
| 2022 Q3 | -801.73 Thousand CAD | -39.51% |
| 2022 Q4 | 333.88 Thousand CAD | 141.65% |
| 2022 Q2 | -574.69 Thousand CAD | 36.35% |
| 2022 FY | -1.48 Million CAD | 14.2% |
| 2021 FY | -1.72 Million CAD | 54.58% |
| 2021 Q1 | -495.89 Thousand CAD | 69.82% |
| 2021 Q4 | -469.18 Thousand CAD | -21902.04% |
| 2021 Q3 | 2152.00 CAD | 100.28% |
| 2021 Q2 | -763.64 Thousand CAD | -53.99% |
| 2020 Q3 | 450.67 Thousand CAD | 121.58% |
| 2020 FY | -3.8 Million CAD | -6.21% |
| 2020 Q1 | -520.82 Thousand CAD | -581.61% |
| 2020 Q2 | -2.08 Million CAD | -300.92% |
| 2020 Q4 | -1.64 Million CAD | -464.54% |
| 2019 Q3 | -610.77 Thousand CAD | 64.36% |
| 2019 Q2 | -1.71 Million CAD | -45.5% |
| 2019 Q4 | -76.41 Thousand CAD | 87.49% |
| 2019 Q1 | -1.17 Million CAD | 79.4% |
| 2019 FY | -3.57 Million CAD | 69.89% |
| 2018 Q1 | -1.41 Million CAD | 47.41% |
| 2018 FY | -11.88 Million CAD | -64.33% |
| 2018 Q4 | -5.71 Million CAD | -118.69% |
| 2018 Q3 | -2.61 Million CAD | -20.72% |
| 2018 Q2 | -2.16 Million CAD | -52.82% |
| 2017 Q1 | -94.55 Thousand CAD | 20.86% |
| 2017 Q2 | -880.73 Thousand CAD | -831.44% |
| 2017 Q3 | -1.08 Million CAD | -23.7% |
| 2017 FY | -7.23 Million CAD | -131.26% |
| 2017 Q4 | -2.69 Million CAD | -147.34% |
| 2016 Q3 | -106.02 Thousand CAD | -297.5% |
| 2016 Q1 | -32.29 Thousand CAD | -90.42% |
| 2016 Q2 | -26.67 Thousand CAD | 17.41% |
| 2016 FY | -3.12 Million CAD | -4907.47% |
| 2016 Q4 | -119.47 Thousand CAD | -12.69% |
| 2015 Q4 | -16.96 Thousand CAD | -895.36% |
| 2015 FY | -62.45 Thousand CAD | 0.0% |
| 2015 Q3 | -1704.00 CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -6.78 Million CAD | 81.206% |
| Asep Medical Holdings Inc | -8.22 Million CAD | 84.509% |
| BetterLife Pharma Inc. | -2.88 Million CAD | 55.886% |
| BioVaxys Technology Corp. | -7.68 Million CAD | 83.421% |
| ChitogenX Inc. | -1.55 Million CAD | 17.988% |
| Rapid Dose Therapeutics Corp. | -4.3 Million CAD | 70.406% |
| Defence Therapeutics Inc. | -13.19 Million CAD | 90.34% |
| Entheon Biomedical Corp. | -300 Thousand CAD | -324.822% |
| Gemina Laboratories Ltd. | -5.21 Million CAD | 75.57% |
| Glow Lifetech Corp. | -1.64 Million CAD | 22.553% |
| Lexston Life Sciences Corp. | -867.71 Thousand CAD | -46.877% |
| Pharmala Biotech Holdings Inc. | -779.81 Thousand CAD | -63.433% |
| Doseology Sciences Inc. | -339.84 Thousand CAD | -275.012% |
| MYND Life Sciences Inc. | -1.51 Million CAD | 16.035% |
| Nova Mentis Life Science Corp. | -1.22 Million CAD | -4.088% |
| PharmaTher Holdings Ltd. | -3.11 Million CAD | 59.09% |
| Telescope Innovations Corp. | -5.72 Million CAD | 77.747% |